1h Free Analyst Time
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110α is a protein encoded by the PIK3CA gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development.
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 26 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 3, 12, 1 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Immunology and Infectious Disease which include indications Breast Cancer, Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Endometrial Cancer, Multiple Myeloma (Kahler Disease), Burkitt Lymphoma, Colorectal Cancer, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Metastatic Breast Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), CNS Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Hematological Tumor, Hepatocellular Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Lymphoma, Mantle Cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Mutational Disorders, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Thymoma (Thymic Epithelial Tumor).
The latest report Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
- The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
- The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Overview
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- Applied Therapeutics Inc
- AstraZeneca Plc
- Bayer AG
- Chia Tai Tianqing Pharmaceutical Group Co Ltd.
- Curis Inc
- Genentech Inc
- GlaxoSmithKline Plc
- Millennium Pharmaceuticals Inc
- Novartis AG
- Onconova Therapeutics Inc
- Petra Pharma Corp
- PIQUR Therapeutics AG
- Shanghai Haihe Biopharma Co Ltd
- Sichuan Sinovation Bio-technology Co Ltd
- SignalRx Pharmaceuticals Inc
- Sphaera Pharma Pte Ltd
- Yangtze River Pharmaceutical Group
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
- AL-58922 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alpelisib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BAY-1082439 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bimiralisib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- buparlisib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fimepinostat - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GDC-0077 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HHCYH-33 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NSC-765844 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- omipalisib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ON-146040 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Petra-03 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PQR-514 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- serabelisib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SF-2523 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule 2 to Inhibit PIK3CA for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit PI3K Alpha for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit PIK3CA and MTOR for Colorectal Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit PIK3CA for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit PI3K Alpha for Breast Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit PIK3CA and PIK3CG for Solid Tumors - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SN-202 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SPR-965 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- taselisib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- WX-008 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
- Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
- Featured News & Press Releases
- Appendix
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Products under Development by Companies, H1 2020 (Contd..4), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Pipeline by Advenchen Laboratories LLC, H1 2020
- Pipeline by Applied Therapeutics Inc, H1 2020
- Pipeline by AstraZeneca Plc, H1 2020
- Pipeline by Bayer AG, H1 2020
- Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H1 2020
- Pipeline by Curis Inc, H1 2020
- Pipeline by Genentech Inc, H1 2020
- Pipeline by GlaxoSmithKline Plc, H1 2020
- Pipeline by Millennium Pharmaceuticals Inc, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by Onconova Therapeutics Inc, H1 2020
- Pipeline by Petra Pharma Corp, H1 2020
- Pipeline by PIQUR Therapeutics AG, H1 2020
- Pipeline by Shanghai Haihe Biopharma Co Ltd, H1 2020
- Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H1 2020
- Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
- Pipeline by Sphaera Pharma Pte Ltd, H1 2020
- Pipeline by Yangtze River Pharmaceutical Group, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Dormant Products, H1 2020 (Contd..2), H1 2020
- Discontinued Products, H1 2020
- Discontinued Products, H1 2020 (Contd..1), H1 2020
- Discontinued Products, H1 2020 (Contd..2), H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- Applied Therapeutics Inc
- AstraZeneca Plc
- Bayer AG
- Chia Tai Tianqing Pharmaceutical Group Co Ltd.
- Curis Inc
- Genentech Inc
- GlaxoSmithKline Plc
- Millennium Pharmaceuticals Inc
- Novartis AG
- Onconova Therapeutics Inc
- Petra Pharma Corp
- PIQUR Therapeutics AG
- Shanghai Haihe Biopharma Co Ltd
- Sichuan Sinovation Bio-technology Co Ltd
- SignalRx Pharmaceuticals Inc
- Sphaera Pharma Pte Ltd
- Yangtze River Pharmaceutical Group
